Rat Apoptosis Regulator Bcl-2 (BCL2) ELISA Kit

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Rat Apoptosis Regulator Bcl-2 (BCL2) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Rat Apoptosis Regulator Bcl-2 (BCL2) concentrations in tissue homogenates, cell lysates and other biological fluids.
Documents del producto
Product specifications
Category | ELISA Kits |
Immunogen Target | Apoptosis Regulator Bcl-2 (BCL2) |
Reactivity | Rat |
Detection Method | Colorimetric |
Assay Data | Quantitative |
Assay Type | Sandwich |
Test Range | 0.156 ng/ml - 10 ng/ml |
Sensitivity | 0.1 ng/ml |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Size 1 | 96 tests |
Size 2 | 5 × 96 tests |
Size 3 | 10 × 96 tests |
Form | Lyophilized |
Tested Applications | ELISA |
Sample Type | Tissue homogenates, cell lysates and other biological fluids. |
Availability | Shipped within 5-7 working days. The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request. |
Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
Dry Ice | No |
UniProt ID | P49950 |
Gene ID | 24224 |
NCBI Accession | NP_058689.1 |
Alias | Bcl-2,PPP1R50,B-Cell CLL/Lymphoma 2 |
Background | Elisa kits for BCL2 |
Status | RUO |
Note | Validity: The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
BCL2 apoptosis regulator (BCL2) is a key anti-apoptotic protein that plays a central role in regulating cell survival by preventing mitochondrial-mediated apoptosis BCL2 functions by inhibiting the release of pro-apoptotic factors, such as cytochrome c, from the mitochondria, thus preventing caspase activation and cell death It is highly expressed in various tissues, particularly in immune cells and neurons, where it protects against apoptosis and supports cell longevity Dysregulation of BCL2 expression has been associated with several diseases, including cancer, where its overexpression allows tumor cells to evade cell death, contributing to tumor progression and resistance to therapy BCL2 is also implicated in neurodegenerative diseases, where its dysfunction can lead to excessive neuronal death BCL2 interacts with other members of the Bcl-2 family, including pro-apoptotic proteins like BAX, to finely tune apoptotic signaling and maintain cellular homeostasis Its role in regulating apoptosis and survival pathways makes BCL2 a critical factor in development, aging, and disease management
Related Products

BCL2 antibody
This gene encodes an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Alternative splicing results in multiple transcript variants.
Ver Producto
BCL2 antibody
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor(APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release(PubMed:17418785).
Ver Producto